<DOC>
	<DOC>NCT02423174</DOC>
	<brief_summary>The objective of the clinical trial is to determine the suitability of the FMwand Ferromagnetic Surgical System for Total Mesorectal Excision Surgery.</brief_summary>
	<brief_title>Eval. of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Confirmed rectal cancer to the lower twothirds of the rectum (higher and T2 N0 or N+) Amenable for standard surgery procedures using electrocautery, argon beam, lasers or other conventional tissue removal modalities ECOG status ≤ 2 Life expectancy &gt;3 months Age ≥ 18 years old Age ≤ 80 years old Ability to provide written informed consent and HIPAA forms prior to admission to this study Willingness to meet all of the expected requirements of this clinical protocol Patient with metastasis History of radiotherapy or chemotherapy for the treatment of rectal cancer Uremia BUN&gt;40 Hemodialysis Existing urinary or fecal incontinence Pregnant or lactating Previously diagnosed coagulopathy or bleeding diathesis Currently, or within the previous 10 days prior to surgery, taking any medications that would produce bleeding diathesis including but not limited to, Plavix, warfarin, NSAIDs, clopidogrel, ticlopidine or valproic acid History of significant cardiac disorders that would necessitate special fluid management protocols History of acute myocardial infarction and/or acute angina INR &gt;1.4 in the 24 hours prior to surgery PTT &gt;40 in the 24 hours prior to surgery Platelet count &lt;100K in the 24 hours prior to surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>